Recursion Pharmaceuticals, Inc.
RXRX
$3.16
-$0.15-4.53%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -15.08% | 11.07% | 26.92% | -32.98% | 30.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.08% | 11.07% | 26.92% | -32.98% | 30.14% |
| Cost of Revenue | -10.16% | 14.51% | 51.87% | 66.86% | 54.63% |
| Gross Profit | 9.43% | -15.06% | -56.75% | -91.64% | -59.09% |
| SG&A Expenses | -23.95% | -15.57% | 0.54% | 61.46% | 69.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.26% | 5.15% | 34.87% | 65.31% | 58.76% |
| Operating Income | 14.17% | -4.53% | -35.84% | -81.51% | -62.34% |
| Income Before Tax | 19.36% | 1.90% | -38.75% | -86.89% | -70.69% |
| Income Tax Expenses | -28,737.50% | -803.55% | 88.03% | 97.15% | 100.30% |
| Earnings from Continuing Operations | 20.06% | 2.61% | -39.06% | -89.42% | -73.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.06% | 2.61% | -39.06% | -89.42% | -73.14% |
| EBIT | 14.17% | -4.53% | -35.84% | -81.51% | -62.34% |
| EBITDA | 18.31% | 1.90% | -28.13% | -75.82% | -58.99% |
| EPS Basic | 41.98% | 32.35% | 10.74% | -17.10% | -8.88% |
| Normalized Basic EPS | 40.08% | 30.45% | 10.90% | -14.06% | -6.08% |
| EPS Diluted | 41.98% | 32.35% | 10.74% | -17.10% | -8.88% |
| Normalized Diluted EPS | 40.08% | 30.45% | 10.90% | -14.06% | -6.08% |
| Average Basic Shares Outstanding | 41.47% | 51.98% | 63.55% | 62.93% | 57.12% |
| Average Diluted Shares Outstanding | 41.47% | 51.98% | 63.55% | 62.93% | 57.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |